AstraZeneca says 4th-Q earns triple on cancer drugs sales

AstraZeneca is working with the University of Oxford to adapt its COVID-19 vaccine to protect against new strains of the virus as public health officials raise concerns about mutations that may make the virus more resistant to existing vaccines

The comments came as Astra-Zeneca said fourth-quarter net income rose to $1.01 billion from $313 million in the same quarter a year earlier. Drug sales increased 11% to $7.41 billion, driven by a 24% increase in cancer treatments.

The company posted $2 million of revenue from its COVID-19 vaccine, which it has pledged to supply on a non-profit basis during the pandemic, and said it would begin reporting sales of the vaccine separately beginning in the next quarter.

———

Be the first to comment

Leave a Reply

Your email address will not be published.


*